Cytokine & Growth Factor Reviews
Volume 21, Issue 4 , Pages 263-273 , August 2010

High avidity cytokine autoantibodies in health and disease: Pathogenesis and mechanisms

  • Masato Watanabe

      Affiliations

    • Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo 181-8611, Japan
    • ,
  • Kanji Uchida

      Affiliations

    • Department of Anesthesiology, Tokyo University Graduate School of Medicine, Tokyo 113-8655, Japan
    • ,
  • Kazuhide Nakagaki

      Affiliations

    • College of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino, Tokyo 180-8602, Japan
    • ,
  • Bruce C. Trapnell

      Affiliations

    • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, United States
    • ,
  • Koh Nakata

      Affiliations

    • Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Asahimachi-dohri 1-754, Niigata 951-8520, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 25 227 0847; fax: +81 25 227 0377.

References 

  1. Mogensen KE, Daubas P, Gresser I, Sereni D, Varet B. Patient with circulating antibodies to alpha-interferon. Lancet. 1981;2:1227–1228
  2. Vallbracht A, Treuner J, Flehmig B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature. 1981;289:496–497
  3. Suzuki H, Akama T, Okane M, Kono I, Matsui Y, Yamane K, et al. Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis. Arthritis Rheum. 1989;32:1528–1538
  4. Svenson M, Poulsen LK, Fomsgaard A, Bendtzen K. IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand J Immunol. 1989;29:489–492
  5. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today. 1998;19:209–211
  6. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest. 1993;92:2533–2539
  7. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood. 1998;91:2054–2061
  8. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest. 1995;95:1974–1978
  9. Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K. Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. Blood. 1997;90:2376–2380
  10. Kitamura T, Tanaka N, Watanabe J, Uchida , Kanegasaki S, Yamada Y, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999;190:875–880
  11. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;162:658–662
  12. Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009;113:2547–2556
  13. Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007;581:2017–2021
  14. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med. 2007;356:567–579
  15. Kurdowska A, Noble JM, Grant IS, Robertson CR, Haslett C, Donnelly SC. Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Crit Care Med. 2002;30:2335–2337
  16. Kurdowska A, Noble JM, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR. Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med. 2001;163:463–468
  17. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004;103:1089–1098
  18. Madariaga L, Amurrio C, Martin G, Garcia-Cebrian F, Bicandi J, Lardelli P, et al. Detection of anti-interferon-gamma autoantibodies in subjects infected by Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 1998;2:62–68
  19. Elkarim RA, Mustafa M, Kivisakk P, Link H, Bakhiet M. Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest. 1998;28:295–299
  20. Kurdowska AK, Noble JM, Adcock JE. Interleukin-8 and anti-interleukin-8 autoantibodies in gingival crevicular fluid from patients with periodontitis. J Periodontal Res. 2003;38:73–78
  21. Dicou E, Nerrière V. Evidence that natural autoantibodies against the nerve growth factor (NGF) may be potential carriers of NGF. J Neuroimmunol. 1997;75:200–203
  22. Kurdowska A, Miller EJ, Noble JM, Baughman RP, Matthay MA, Brelsford WG, et al. Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome. J Immunol. 1996;157:2699–2706
  23. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum. 2002;46:2384–2391
  24. Hara A, Wada T, Kitajima S, Toyama T, Okumura T, Kitagawa K, et al. Combined pure red cell aplasia and autoimmune hemolytic anemia in systemic lupus erythematosus with anti-erythropoietin autoantibodies. Am J Hematol. 2008;83:750–752
  25. Patel SY, Ding L, Brown MR, Lantz L, Gay T, Cohen S, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol. 2005;175:4769–4776
  26. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol. 2008;180:647–654
  27. Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3:e289
  28. Graudal NA, Svenson M, Tarp U, Garred P, Jurik AG, Bendtzen K. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis. 2002;61:598–602
  29. Jouvenne P, Fossiez F, Banchereau J, Miossec P. High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study. Scand J Immunol. 1997;46:413–418
  30. Sjöwall C, Ernerudh J, Bengtsson AA, Sturfelt G, Skogh T. Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus. J Autoimmun. 2004;22:315–323
  31. Krupa A, Kato H, Matthay MA, Kurdowska AK. Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1105–L1113
  32. Suzuki H, Takemura H, Yoshizaki K, Koishihara Y, Ohsugi Y, Okano A, et al. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol. 1994;152:935–942
  33. Galle P, Svenson M, Bendtzen K, Hansen MB. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol. 2004;34:3267–3275
  34. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527–2539
  35. Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389–396
  36. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–475
  37. Tzioufas AG, Kokori SI, Petrovas CI, Moutsopoulos HM. Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus: correlation with anemia. Arthritis Rheum. 1997;40:2212–2216
  38. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996;334:630–633
  39. Döffinger R, Helbert MR, Barcenas-Morales G, Yang K, Dupuis S, Ceron-Gutierrez L, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2004;38:e10–e14
  40. Höflich C, Sabat R, Rosseau S, Temmesfeld B, Slevogt H, Docke WD, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood. 2004;103:673–675
  41. Tanaka Y, Hori T, Ito K, Fujita T, Ishikawa T, Uchiyama T. Disseminated Mycobacterium avium complex infection in a patient with autoantibody to interferon-gamma. Intern Med. 2007;46:1005–1009
  42. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829–1836
  43. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350:2068–2079
  44. Mathis D, Benoist C. Aire. Annu Rev Immunol. 2009;27:287–312
  45. Homann C, Hansen MB, Graudal N, Hasselqvist P, Svenson M, Bendtzen K, et al. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. Scand J Immunol. 1996;44:623–629
  46. Fudala R, Krupa A, Stankowska D, Allen TC, Kurdowska AK. Anti-interleukin-8 autoantibody:interleukin-8 immune complexes in acute lung injury/acute respiratory distress syndrome. Clin Sci (Lond). 2008;114:403–412
  47. Fudala R, Krupa A, Matthay MA, Allen TC, Kurdowska AK. Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol. 2007;293:L364–L374
  48. Takemura H, Suzuki H, Yoshizaki K, Ogata A, Yuhara T, Akama T, et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum. 1992;35:940–943
  49. von Wussow P, Jakschies D, Hartung K, Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int. 1988;8:225–230
  50. Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom-Davis J, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132:128–136
  51. Ikeda Y, Toda G, Hashimoto N, Umeda N, Miyake K, Yamanaka M, et al. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Clin Exp Immunol. 1991;85:80–84
  52. Capini CJ, Richardson MW, Hendel H, Sverstiuk A, Mirchandani J, Regulier EG, et al. Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. Biomed Pharmacother. 2001;55:23–31
  53. Ikeda Y, Miyake K, Toda G, Yamada H, Yamanaka M, Oka H. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease. J Gastroenterol Hepatol. 1989;4:411–418
  54. Bost KL, Hahn BH, Saag MS, Shaw GM, Weigent DA, Blalock JE. Individuals infected with HIV possess antibodies against IL-2. Immunology. 1988;65:611–615
  55. Strobel P, Marx A, Zettl A, Muller-Hermelink HK. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today. 2005;35:805–811
  56. Shiono H, Wong YL, Matthews I, Liu JL, Zhang W, Sims G, et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol. 2003;15:903–913
  57. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology. 2001;57:1579–1582
  58. Colonna M, Krug A, Cella M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol. 2002;14:373–379
  59. Bendriss-Vermare N, Barthelemy C, Durand I, Bruand C, Dezutter-Dambuyant C, Moulian N, et al. Human thymus contains IFN-alpha-producing CD11c(−), myeloid CD11c(+), and mature interdigitating dendritic cells. J Clin Invest. 2001;107:835–844
  60. Hansen MB, Svenson M, Abell K, Varming K, Nielsen HP, Bertelsen A, et al. Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans. Eur J Clin Invest. 1994;24:212–218
  61. Ohmoto Y, Ogushi F, Muraguchi M, Yamakawa M, Sone S. Age-related increase of autoantibodies to interleukin 1 alpha in healthy Japanese blood donors. J Med Invest. 1997;44:89–94
  62. Svenson M, Bagge Hansen M, Bendtzen K. Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera. Scand J Immunol. 1990;32:695–701
  63. Hansen MB, Svenson M, Diamant M, Bendtzen K. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine. 1993;5:72–80
  64. Laricchia Robbio L, Moscato S, Genua A, Liberati AM, Revoltella RP. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol. 1997;173:219–226
  65. Revoltella RP, Laricchia Robbio L, Moscato S, Vinante F, Fasciani A, Liberati AM, et al. Naturally-occurring anti-G-CSF antibodies produced by human cord blood B-cell lines infected with Epstein-Barr virus. Hematol J. 2001;2:161–171
  66. Revoltella RP, Laricchia Robbio L, Liberati AM, Reato G, Foa R, Funaro A, et al. Antibodies binding granulocyte-macrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein–Barr virus in vitro. Cell Immunol. 2000;204:114–127
  67. Tiberio L, Caruso A, Pozzi A, Rivoltini L, Morelli D, Monti E, et al. The detection and biological activity of human antibodies to IL-2 in normal donors. Scand J Immunol. 1993;38:472–476
  68. Balleari E, Bason C, Visani G, Gobbi M, Ottaviani E, Ghio R. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase. Haematologica. 1994;79:7–12
  69. Sylvester I, Yoshimura T, Sticherling M, Schroder JM, Ceska M, Peichl P, et al. Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum. J Clin Invest. 1992;90:471–481
  70. Garrone P, Djossou O, Fossiez F, Reyes J, Ait-Yahia S, Maat C, et al. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Mol Immunol. 1996;33:649–658
  71. Hayashida K, Kitamura T, Gorman DM, Arai K, Yokota T, Miyajima A. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci U S A. 1990;87:9655–9659
  72. Sims JE, Acres RB, Grubin CE, McMahan CJ, Wignall JM, March CJ, et al. Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci U S A. 1989;86:8946–8950
  73. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149–1157
  74. Tavernier J, Tuypens T, Plaetinck G, Verhee A, Fiers W, Devos R. Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit. Proc Natl Acad Sci U S A. 1992;89:7041–7045
  75. Liu Y, Wei SH, Ho AS, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immunol. 1994;152:1821–1829
  76. Cohen B, Novick D, Barak S, Rubinstein M. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol. 1995;15:4208–4214
  77. Monti E, Pozzi A, Tiberio L, Morelli D, Caruso A, Villa ML, et al. Purification of interleukin-2 antibodies from healthy individuals. Immunol Lett. 1993;36:261–266
  78. Ross C, Hansen MB, Schyberg T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol. 1990;82:57–62
  79. Courtney LP, Phelps JL, Karavodin LM. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology. 1994;28:223–232
  80. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993;151:1235–1244
  81. Sato J, Hamaguchi N, Doken K, Gotoh K, Ootsu K, Iwasa S, et al. Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy. 1993;6:225–231
  82. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311:1924–1927
  83. Laver J, Duncan E, Abboud M, Gasparetto C, Sahdev I, Warren D, et al. High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. J Pediatr. 1990;116:627–632
  84. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature. 2005;435:590–597
  85. Ragnhammar P, Friesen HJ, Frodin JE, Lefvert AK, Hassan M, Osterborg A, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood. 1994;84:4078–4087
  86. Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res. 1990;50:6708–6715
  87. Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol. 2005;16(Suppl. 1):S67–S69
  88. Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, Fazio R, et al. Serial immunoprecipitation assays for interferon—(IFN)-beta antibodies in multiple sclerosis patients. Eur Cytokine Netw. 2003;14:154–157
  89. Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of Aire control of T cell tolerance. Immunity. 2005;23:227–239
  90. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298:1395–1401
  91. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol. 1996;14:101–130
  92. ElKarim R, Granert C, Lindquist L, Link H, Bakhiet M. Levels of gamma interferon and interleukin-4 are inversely related to the levels of their corresponding autoantibodies in patients with lower respiratory tract infection. Infect Immun. 1999;67:3051–3054
  93. Evans M, Abdou NI. Anti-interleukin-6 and soluble interleukin-6 receptor in systemic lupus erythematosus. Lupus. 1994;3:161–166
  94. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006;102:244–251
  95. Zhang W, Liu JL, Meager A, Newsom-Davis J, Willcox N. Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-gamma responses of healthy CD4+ T cells. J Neuroimmunol. 2003;139:102–108
  96. Fomsgaard A, Svenson M, Bendtzen K. Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol. 1989;30:219–223
  97. Tsuchiyama L, Wong T, Kieran J, Boyle P, Penza D, Wetzel GD. Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals. Hum Antibodies Hybridomas. 1995;6:73–76
  98. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752–762
  99. Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J, et al. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology. 1999;97:526–532
  100. Slavikova M, Schmeisser H, Kontsekova E, Mateicka F, Borecky L, Kontsek P. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J Interferon Cytokine Res. 2003;23:143–147
  101. Elkarim RA, Mustafa M, Link H, Bakhiet M, Ekerfelt C, Vrethem M, et al. Induction of neutralizing autoantibodies to interferon-gamma in patients with polyneuropathy. Hum Antibodies. 1999;9:55–60
  102. Klyushnik TP, Sergienko NS, Danilovskaya EV, Goryunova AV, Maslova OI. Autoantibodies to nerve growth factor in disorders of mental development in infants. Neurosci Behav Physiol. 2001;31:165–167

PII: S1359-6101(10)00028-6

doi: 10.1016/j.cytogfr.2010.03.003

Cytokine & Growth Factor Reviews
Volume 21, Issue 4 , Pages 263-273 , August 2010

Article Tools

* Image Usage & Resolution